Table 1 |
||||
|
Cell viability tests on Tera-1 and HEK-293 cells. |
||||
|
Experimenta |
Tera-1 |
HEK-293 |
||
|
|
||||
|
PI assayb |
Annexin Vc |
PI assayb |
Annexin Vc |
|
|
|
||||
|
-5FC; -Transf. |
9.2 ± 2.3 |
ND |
7.7 ± 1.5 |
ND |
|
|
||||
|
-5FC; no-RCD |
9.0 ± 1.7 |
ND |
7.4 ± 1.7 |
ND |
|
|
||||
|
-5FC; mNUS-RCD |
8.8 ± 2.9 |
ND |
7.8 ± 2.1 |
ND |
|
|
||||
|
-5FC; CMV-RCD |
9.9 ± 2.5 |
ND |
8.2 ± 2.2 |
ND |
|
|
||||
|
+5FC; -Transf. |
9.4 ± 2.1 |
10.9 ± 3.3 |
7.4 ± 1.8 |
8.7 ± 2.3 |
|
|
||||
|
+5FC; no-RCD |
9.1 ± 2.5 |
10.7 ± 2.6 |
7.7 ± 1.6 |
8.6 ± 2.9 |
|
|
||||
|
+5FC; mNUS-RCD |
59.5 ± 6.4 |
59.1 ± 3.9 |
7.8 ± 1.7 |
8.4 ± 2.8 |
|
|
||||
|
+5FC; CMV-RCD |
67.3 ± 7.5 |
64.9 ± 5.6 |
73.8 ± 11.3 |
75.5 ± 8.6 |
|
|
||||
|
aCell viability tests shown on this table were done 24 hours after application of 5FC. "-5FC" means "no 5FC was added", "+FC" marks experiments with the addition of 5FC to the medium. "-Transf.", "no-RCD", "mNUS-RCD" and "CMV-RCD" mean "no transfection", "transfection with no-RCD construct", "transfection with mNUS-RCD" and "transfection with CMV-RCD", accordingly. bPropidium iodide tests were done at least in quadruplicates. The data represent integral proportion of necrotic and apoptotic cells. cAnnexin V assay was performed for all the experiments with the addition of 5FC to the medium. Tests were done in triplicates. The data represent integral proportion of necrotic and apoptotic cells. |
||||
|
Kuzmin et al. BMC Biotechnology 2010 10:58 doi:10.1186/1472-6750-10-58 |
||||
